CytoSorbents Corporation (CTSO)

[techxen]

Re: "Cytosorb will probably need additional cash"

The company utilized the ATM with Cantor Fitzgerald in Q3 selling approximately 48,000 shares at an average price of $12.60, which generated net proceeds of approximately $605,000. They will probably continue to use the ATM through Q4, plus they could qualify for the $5M Term B loan if they so choose before March 31, 2019 pending them meeting the 2018 revenue qualifications. The company already said they have sufficient cash to fund operating and clinical trial needs well into the second half of 2020, so any additional funds they raise the remainder of the year should put them in a strong position going forward.